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Abstract 
Cancer remains a major and leading health problem worldwide. Lack of early diagnosis, 
chemoresistance and recurrence of cancer means vast research and development are required 
in this area. The complexity of the tumor microenvironment in the biological milieu poses 
greater challenges in having safer, selective and targeted therapies. Existing strategies such as 
chemotherapy, radiotherapy and anti-angiogenic therapies moderately improve progression-
free survival, however, they come with side-effects that reduce quality of life. Thus, targeting 
potential candidates in the microenvironment, such as extracellular cathepsin D (CathD) which 
has been known to play major pro-tumorigenic roles in breast and ovarian cancers, could be a 
breakthrough in cancer treatment, specially using novel treatment modalities such as 
immunotherapy and nanotechnology-based therapy. This chapter discusses CathD as a pro-
cancerous, more specifically a proangiogenic factor, that acts bi-functionally in the tumor 







Globally, more than 2.28 million new cases of breast and ovarian cancers are diagnosed, with 
approximately 810,000 deaths each year [1-3]. Thus, tackling these two major cancers remains 
a daunting task for clinicians and researchers. By the year 2025, it is estimated that, globally, 
there will be a surge in the number of cancer cases (>20 million annually) - an alarming statistic 
that has compelled researchers to expedite research to discover newer targets and develop more 
potent therapeutic compounds to overcome drug resistance as well as eradicate cancer cells 
from the biological setting [4]. However, the disease remains a global challenge due to the lack 
of early diagnosis, the inherent biological complexity and the high demands for designing safer 
and selective drugs to restrict tumor growth [5]. 
 
Although researchers have a much better understanding of many characteristics of cancer [6], 
the complex systems that allow tumors to form remains to be solved. It is the complex crosstalk 
between the cellular and non-cellular components of the host organ which, under the influence 
of the tumor cells, help create a niche for tumors to grow uncontrollably, invade local tissue, 
evade local immune-mediated destruction, and stimulate angiogenesis and metastasis [7]. This 
newly formed niche where tumors sit and grow is known as the tumor microenvironment 
(Figure 1). A number of cells, such as cancer-associated fibroblasts (CAFs), immune cells, 
adipocytes, neuroendocrine cells, the blood, and lymphatic vascular networks, and tumor cells, 
help build this niche [8]. Once tumors start to grow in this hypoxic microenvironment, where 
the normal cell and tissue homeostasis is dysregulated, they secrete both pro- and anti-
tumorigenic growth factors, cytokines, extracellular vesicles, extracellular matrix (ECM) 
proteins and ECM-remodeling enzymes that trigger a switch to a more pro-tumorigenic 
response from the surrounding cells [7]. For instance, CAFs, pericytes, endothelial cells (ECs) 
from local microvasculature and tumor cells secrete a wide range of enzymes that effectively 
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degrade the surrounding ECM to allow tumor cell invasion of the host tissue and microvascular 
ECs to migrate, proliferate and form a new blood supply to feed the growing tumor [7, 9]. A 
number of these enzymes have been discovered and characterized over the years such as 
metalloproteases, lysyl oxidases and cysteine and aspartyl cathepsins [7]. Interestingly, over 
the last couple of decades, aspartyl cathepsins, particularly cathepsin D (CathD), have gained 
increased attention due to their extracellular presence in the tumor microenvironment and 
reported roles in tumor development and metastasis as well as their potential as therapeutic 
targets [10-18]. 
 
CathD is a ubiquitous, aspartic endoproteinase that is expressed in all human tissues. 
Physiologically, it resides in the lysosomes, proteolytically degrading unfolded or non-
functional proteins. CathD is involved in essential biological processes, such as during 
development and maintaining tissue homeostasis, where the enzyme is believed to act 
proteolytically outside its acidic milieu [19]. Thus, dysregulation of CathD expression and/or 
function is associated with pathologies such as atherosclerosis, neurological, dermatological 
disorders and cancer [20]. For instance, CathD secreted from tumor cells into the extracellular 
space has been suggested to play an important role in invasion and metastasis of breast cancer 
[21, 22]. Winiarski et al. also reported an overexpression and secretion of CathD in cancerous 
tissue and ascites of ovarian cancer patients [23], which enhanced proangiogenic responses 
such as proliferation, migration and angiogenic tube formation in local omental microvascular 
ECs [11]. Overexpression and hypersecretion of CathD have now been demonstrated in other 
cancer types including lung, prostate, endometrial, malignant glioma and melanoma, and the 
protein is considered to be a prognostic biomarker in breast cancer [24] and a potential marker 
in predicting prognosis of endometrial adenocarcinoma [25]. These data, along with unresolved 
complexity of the microenvironment which facilitates tumor cell invasion of local host tissue, 
highlights the importance of further research on the biological aspects and therapeutic purpose 
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of CathD in cancer development. This chapter focuses on cancer cell-secreted CathD in the 
tumor microenvironment and its role in tumor invasion, angiogenesis and metastasis, and also 
gives a brief perspective on the possibility of targeting extracellular CathD therapeutically. 
 
 







Processing of Cathepsin D 
The synthesis process of CathD is regulated in the conventional endoplasmic reticulum/Golgi 
pathway. After synthesis in the rough endoplasmic reticulum as inactive preprocathepsin D (43 
kDa), it is further cleaved and glycosylated to form 52 kDa procathepsin D (pCathD) containing 
two N-linked oligosaccharides modified with mannose 6-phosphate (M6P) residues at 
asparagine residues 70 and 199 [26, 27]. Modified pCathD is then targeted to intracellular 
vesicular structures such as endosomes, lysosomes, and phagosomes both by M6P receptor 
(M6PR)-dependent and -independent pathways [19]. The latter mechanism of targeting is not 
yet understood; however, the sphingolipid activator precursor protein pro-saposin has been 
suggested to be involved [28]. 
Upon entry into the acidic milieu of the late endosome, M6PRs detach from pCathD and 
subsequently, the phosphate group is removed. Low pH- and cysteine protease-induced 
proteolytic cleavage of propeptide (44aa) of pCathD generates an active intermediate form of 
the enzyme [29]. The propeptide (also known as activation peptide) plays an essential role in 
correctly folding, activating and delivering the protein to lysosomes [30, 31]. This peptide, 
which is expressed in, and secreted from, cancer cells, has also been demonstrated to act as a 
growth factor for tumor cells [32]. The intermediate form of CathD is further cleaved to 
generate the mature form (48 kDa) containing a heavy chain (34 kDa) and a light chain (14 
kDa) linked by non-covalent interactions [33]. CathD activity is tightly regulated at pH 3.5 
[34], however, it is now known that the enzyme is active both proteolytically and non-
proteolytically at neutral pH in the cytosol of apoptotic cells and during neurofibrillary 





Physiological roles of CathD as both an intracellular and extracellular protein 
Besides its lysosomal activity, CathD also plays a significant role during fetal development. 
There is a gradual maturation observed in the lysosomal system that correlates with increased 
CathD levels in all tissues [37]. Mice deficient in CathD survive during fetal development, but 
die around 1 month after birth due to significant neurodegeneration [38], indicating the 
protein’s essential role in developmental biology. Further studies demonstrated that congenital 
mutations in the CathD gene lead to a reduction in expression and subsequent production of an 
enzymatically inactive protein that results in neurodegenerative disease in dogs and humans 
[39-44]. In a recent study, an association was shown between CathD deficiency and 
Parkinson’s disease [45]. Interestingly, increased CathD expression and activity in cardiac cells 
is associated with heart failure in postpartum female mice [46]. Higher CathD levels also 
correlate with increasing apoptosis in the cerebellum and this has now been suggested to play 
a role in the pathogenesis of autism [47].  
Other functions of CathD, related to its functional activity, have also been suggested. For 
instance, CathD-induced cleavage of metabolism-associated intracellular proteins, activation 
and degradation of polypeptide hormones and growth factors such as plasminogen, prolactin, 
endostatin, osteocalcin, thyroglobulin, insulin-like growth factor binding proteins (IGFBP) and 
secondary lymphoid tissue chemokine (SLC); activation of enzymatic precursors of CathL, 
CathB and transglutaminase 1; and processing of the enzyme activators and inhibitors 
prosaposin and cystatin C, reviewed in [19]. 
Although CathD mainly acts in the lysosome, in the last 2 decades its role in the extracellular 
space has been explored extensively. CathD differentiates from other aspartic endopeptidases 
in its packaging and sorting process. For instance, it has been known for a while that, 
physiologically, pCathD is sequestered to the lysosome and not secreted extracellularly. 
However, now we know that under some conditions, pCathD/CathD can escape the 
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conventional ER/Golgi-dependent targeting pathway and be secreted from cells. The most 
probable explanation is that over-expression of pCathD surpasses the limited number of M6PR 
binding sites available and thus, the protein accumulates in the cytosol and is subsequently 
secreted. The secretory mechanism, however, remains somewhat a mystery [48]. It is believed 
that the addition of carbohydrate groups to CathD during post-translational modification may 
determine its destiny [49]. For instance, tunicamycin, a glycosylation inhibitor, produced an 
unglycosylated form of CathD that was found to be secreted from cultured liver cells, 
suggesting that lysosomal enzyme-linked carbohydrate structures may play a crucial role in 
directing these enzymes [49]. In the case of secreted CathD, it is understood that these enzymes 
lack M6P residues, which is essential for sorting lysosomal enzymes. Different forms of CathD 
(or pCathD) are now known to be secreted in human, bovine and rat milk and serum, and the 
presence of both pCathD and CathD (34 kDa) was observed in human eccrine sweat and urine 
[50-53]. Interestingly, CathD in human eccrine sweat was found to be proteolytically active at 
sweat pH 5.5 [54], which agreed with the increasing evidence in pathologies such as cancer 
that extracellular CathD may act via its proteolytic-dependent mechanism. 
Expression of CathD in cancer 
CathD is now known to be a major secreted protein found in the cancer microenvironment. 
Over the last 2 decades, studies have shown increased overexpression and hypersecretion of 
CathD in numerous cancer types including ovarian cancer, breast cancer, endometrial cancer, 
lung cancer, malignant glioma, melanoma and prostate cancer (Table 1) [25, 55-68]. In breast 
cancer in particular, CathD is considered as a “marker” associated with metastasis. For 
instance, overexpression of CathD in breast cancer cells correlates with increased risk of 
clinical metastasis and short survival in breast cancer patients [56-58]. Interestingly, increased 
secreted levels of pCathD were also detected in the serum of patients with breast malignancy 
[69]. Another study revealed that the total concentration of CathD in breast cancer tissue was 
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much higher than in other tissues including normal mammary cells [70]. Additionally, Masson 
and colleagues showed, for the first time, that CathD expression is gradually increased as 
preadipocytes differentiate into mature adipocytes in both humans and mice [71]. CathD 
upregulation was also reported in obese subjects and mice, indicating a significant pro-
adipogenesis role of CathD. Since adipocytes play a supportive role in the growth process of 
the breast, and as clinical studies have reported a role of obesity in the incidence of breast 
cancer, CathD upregulation may actually play an indirect role in breast cancer progression. 
A role for CathD has now been shown in the progression of ovarian cancer metastasis. Earlier 
research investigating ovarian cancer suggested that the enhanced level of CathD expression 
was associated with increased cancer cell differentiation and with clinically advanced 
histological type [72, 73]. More recent studies have reported enhanced CathD expression as an 
indicator of malignancy in serous ovarian cancer [74-76], for instance, over 70% of invasive 
ovarian cancers were shown to express CathD [75]. Intriguingly, this finding was contradicted 
by another study which showed that high expression of CathD in the ovarian tumor was 
associated with a favorable survival prognosis [76]. However, our previous work investigating 
omental metastasis of ovarian cancer revealed that a high omental mesothelial expression of 
CathD (close to the metastatic tumor) was associated with poor disease-specific survival (DSS) 
[23]. The study also found that expression of CathD was significantly higher in the omental 
lesion of serous ovarian carcinoma compared with omentum from patients with benign ovarian 







Table 1. Involvement of CathD in the stages of tumor progression in different cancer types. 
Modified from [15] 
Cancer Type Metastasis Invasion Angiogenesis References 
Breast ↑ ↑ ↑ [56-59] 
Ovarian ND ND ↑ [55, 11] 
Prostate ↑ ↑ ↓ [60-62] 
Endometrial ND ↑ ND [68] 
Melanocytic ↑ ↑ ND [63] 
Glioma ↑ ↑ ND [64] 
Lung ND ↑ ND [67] 
↑, increase in effects; ↓, reduction in effects; ND, not determined. 
 
Role of CathD in tumor progression 
Proteolytic-dependent roles 
It is now becoming clear that CathD plays a role in the tumor microenvironment. However, a 
number of questions arise as to how this enzyme with an optimum pH of 3.5 acts proteolytically 
at neutral pHs. Earlier studies suggested that CathD plays an intracellular cytosolic role at 
neutral pH in inducing apoptosis, indicating its proteolytic capability at neutral or near-neutral 
pHs. The enzyme is translocated to the cytosol due to lysosomal membrane permeabilization 
and actively cleaves the BH3-interacting domain (Bid) to form truncated Bid (tBid) [36, 77, 
78]. tBid activates the insertion of Bax into the mitochondrial membrane, leading to the release 
of cytochrome C from mitochondria into the cytosol [79-81]. This apoptotic response was 
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partially delayed by pepstatin A (pepA), an inhibitor of CathD proteolytic activity [78-80], 
suggesting a pro-apoptotic mechanism induced by this enzyme. The role of CathD in inducing 
in vitro apoptosis was further validated when a pan caspase inhibitor (Z-VAD-FMK) induced 
a significant reduction in cell death when given in combination with pepA [82, 83]. 
Additionally, tau protein degradation by cytosolic (i.e. pH 7) proteolytically active CathD has 
been reported in Alzheimer neurofibrillary degradation [35]. These studies strongly suggest 
that CathD is active at pHs higher than the optimum, although it should be noted that other 
works suggested that mutant CathD, deprived of its catalytic activity, was indistinguishable 
from that of the normal enzyme [84, 85]. 
Although it could be argued that a pro-apoptotic role for intracellular CathD may be anti-
tumorigenic, this is in contrast to observations that indicate that not only is CathD secreted from 
tumor cells, but that this extracellular CathD may have key pro-tumorigenic functions. For 
instance, CathD was observed to be overexpressed and hyper-secreted from estrogen-positive 
MCF7 breast cancer cells in in vitro experiments, that resulted in enhanced tumor growth and 
invasion in mammary carcinogenesis [86]. Interestingly, CathD has been shown to cleave cell-
secreted cystatin C, a potent endogenous inhibitor of cysteine and metalloproteinase, at a lower 
pH (pH 5.5- 6.8), similar to the in vivo tumor microenvironment [87]. This suggests that active 
CathD plays a significant role in tumor progression, by preventing the inhibitory action of 
cystatin C on proteases that actively cleave extracellular matrix protein in the tumor stroma, 
allowing cancer cells to invade local tissue. Interestingly, another study demonstrated that 
proteolytically active CathD stimulates the activity of secreted plasminogen activators by 
degrading plasminogen activator inhibitor-1 at pH 6.6 i.e. similar to the tumor 
microenvironment. The authors suggested that this process could be a contributory factor 
involved in triggering a proteolytic cascade facilitating breast cancer cell invasion and 
metastasis [88]. Intriguingly, CathD has also been shown to selectively degrade macrophage 
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inflammatory protein (MIP)-1α (CCL3), MIP-1β (CCL4), and SLC (CCL21) that, in turn, may 
affect the generation of the anti-tumoral immune response, the migration of human breast 
cancer cells, or both processes [89]. 
Although secreted pCathD is generally considered to be proteolytically inactive [90-92], in the 
hypoxic, acidic tumor microenvironment, this precursor form of the enzyme may be converted, 
by an autocatalytic mechanism into the mature form capable of degrading ECM proteins, thus 
releasing basic fibroblast growth factor (bFGF) [10, 59, 93]. The combination of degradation 
of the ECM proteins and released bFGF (Figure 2), a pro-proliferative growth factor, allows 
local tumor and ECs cells to grow and invade local host tissue, aiding tumor metastasis [94].  
 
A more recent study has demonstrated that both pCathD and mature CathD are involved in the 
migration of mesenchymal stem cells (MSCs) to tumor sites [95]. MSCs are known to secrete 
cytokines and chemokines that trigger both pro- and anti-tumorigenic responses in the tumor 
microenvironment. CathD-induced homing of these stem cells to the tumor microenvironment 
facilitates a more aggressive invasion of tumor cells into the surrounding tissue [95]. The study 
further revealed that pCathD acted as a potent stimulator of MSC migration which was 
completely reversed in the presence of pepA. Further investigation revealed an interesting 
phenomenon whereby pCathD in the tumor microenvironment was suggested to be 
uptaken/endocytosed by MSCs and converted into a proteolytically active, mature form of 
CathD, which then induced migration and invasion of MSCs in the cancer stroma [95]. 
However, CathD or pCathD had no effect on cellular proliferation in this study, contradicting 






To answer whether CathD acts in a non-proteolytic manner in the tumor microenvironment, a 
number of studies have been carried out. For example, pCathD has been reported to act as a 
mitogen i.e. a protein-ligand, rather than enzymatically, to stimulate MCF7 cell proliferation 
via an autocrine mechanism [96]. In recent years, numerous studies have emerged that suggest 
a non-proteolytic proangiogenic role for CathD both in vivo and in vitro. For instance, in 
xenografts (3Y-Ad12 cell line transfected with wild-type and/or mutated Asn 231 CathD) in 
an athymic mice model, overexpression of CathD correlated with increased vascular density. 
In these mice, a 1.5-fold and 1.9-fold increase in microvessel density was observed in the 
CathD and CathD-Asn 231 (proteolytically inactive; transfected mice) groups respectively, 
suggesting that CathD induces angiogenic effects via an unknown mechanism other than its 
proteolytic activity [14]. Another study reported that both pCathD and CathD induced 
proliferation and migration of breast cancer cells, fibroblasts and ECs in both a proteolytic 
dependent and independent manner [97]. 
A similar observation was made in epithelial ovarian cancer (EOC). In an investigation on 
potential non-VEGF pathways in inducing tumor angiogenesis, we implicated secreted factors 
such as CathD, CathL and IGFBP7 both in vitro and in vivo (Table 2) [23, 55]. For instance, 
high levels of CathD were found in the ascites of patients suffering from ovarian cancer 
(unpublished data) and CathD was later found to induce proangiogenic effects in disease-
specific local microvascular endothelial cells [11, 55]. An increase in the secretion of CathD 
was also observed from EOC cancer cell lines (SKOV3 and A2780) [55], confirming the in 
vivo phenomenon. Our recent work demonstrated that exogenous CathD induces proliferation 
and migration of human omental microvascular ECs, suggesting a mitogenic role for this 
enzyme [11]. We further confirmed this proangiogenic response by showing activation of 
downstream signaling pathways (ERK1/2 and AKT) in response to CathD in these cells, which 
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agreed with a study where proteolytically inactive CathD was shown to induce human skin 
fibroblast proliferation via activation of the MAPK/ERK1/2 pathway [13] (Figure 2). 
Interestingly, unlike previous observations, we found that CathD was not proteolytically active 
at neutral pHs, but highly active at low, acidic pHs (completely inhibited by pepA), suggesting 
that this enzyme acts non-proteolytically in the pre-tumor microenvironment of the secondary 
tumor site [11]. Our theory is that EOC-secreted CathD locally induces angiogenic responses 
i.e. EC proliferation and migration, during the initial stages of secondary tumor development 
i.e. in a pre-hypoxic, acidic environment. However, once secondary tumor foci are established 
in the omentum, CathD may act proteolytically in the tumor microenvironment to further 
accelerate the metastatic process, as indicated in the aforementioned studies. A similar 
observation was also observed for the EOC-secreted cysteine protease cathepsin L, whereby 
the enzyme non-proteolytically induced omental microvascular EC proliferation, although in 
this case the enzyme remained proteolytically active at neutral pHs [98]. 












Cathepsin D Stimulate EC proliferation and 
migration 
[11] 




and Tie2 receptor 
Ang1: stabilises vessels by 
strengthening endothelial-smooth 
muscle interactions; Tie2R: 
inhibits permeability 
[100] 
Fibroblast growth factor 
(FGF) 












like growth factor 
Binds to epidermal growth factor 
receptor (EGFR) and promote 
angiogenesis 
[103] 
IL6 Induces migration of ECs in the 
mesentery in EOC 
[102, 104] 
IL8 Stimulates VEGF expression and 
the autocrine activation of 
VEGFR2 in ECs 
[105, 102] 
 
A proangiogenic role for CathD may be critical to its reported pro-tumorigenic importance and 
this has been explored in numerous other studies. For instance, CathD was found to induce 
blood vessel formation in the chick chorioallantoic membrane (CAM) model, [106]. A role for 
CathD in angiogenesis was further illustrated by the observation that migration of human 
umbilical vein ECs and in vitro angiogenic tube formation was increased when cells were 
treated with active pure CathD. The observation that pepA completely inhibited these effects 
manner indicated that CathD was proteolytically active in these experiments [106]. As 
mentioned previously, proteolytically active CathD has also been suggested to induce 
angiogenesis in breast cancer by cleaving and releasing ECM-bound pro-angiogenic bFGF 
[59]. The studies described support the suggestion that CathD can induce proangiogenic 
responses via both its proteolytic action and an unknown mechanism that is not dependent on 
its proteolytic activity.  
In contrast, it has also been suggested that CathD activity may be anti-angiogenic.  For instance, 
pCathD secreted by prostate cancer cells was shown to have a possible role in generating 
angiostatin via proteolysis—a specific inhibitor of angiogenesis in vitro as well as in vivo [62], 
suggesting an opposing effect of CathD in angiogenesis.  
There is ample evidence that CathD may induce mitogenic responses in the cells of the tumor 
microenvironment via both proteolytic-dependent and independent mechanisms. Vignon et al. 
demonstrated that the precursor of CathD, pCathD, non-proteolytically induced growth of 
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MCF7 breast cancer cells in vitro [96]. A significant increase in human skin CCD45K 
fibroblast proliferation, motility, and invasive capacity was also observed to be induced by 
proteolytically active and inactive CathD [13]. This prompted an investigation into the target 
receptor molecule on these cells and the authors observed a partial reduction in fibroblast 
proliferation in the presence of M6P and pCathD. Further studies investigating the effects of 
CathD on tumor cells reported rapid growth of human CathD cDNA-transfected 3Y1-Ad12 rat 
tumor cells in vitro, with an increased experimental metastatic potential in vivo [107-109]. In 
addition, the proliferation of 3Y1-Ad12 cells was induced in response to both wild-type and 
mutated (Asn 231, proteolytically inactive) CathD in vitro and in vivo [12, 14]. Based on the 
previous study, the authors tested whether M6P inhibited CathD-induced proliferation and 
concluded that M6P did not compete with CathD interacting with M6PR, indicating a novel 
receptor, probably LDL receptor-related protein 1 (LRP1) [110], involved in inducing a cellular 
response. In the same study, the propeptide (27-44aa) of pCathD was found not to be mitogenic, 




Figure 2. Tumor cell-secreted CathD and its pro-cancerous role in the tumor 
microenvironment. Overexpression of pCathD/CathD leads to its hypersecretion into the 
extracellular space by tumor cells. Proteolytically active CathD cleaves ECM proteins and 
releases the basic fibroblast growth factor (bFGF) that induces angiogenesis. Both pCathD and 
CathD induce tumor cell proliferation in a proteolytic-dependent and independent manner, thus 
utilizing an autocrine mechanism. CathD also induces proliferation of fibroblasts, and both 
proliferation and migration of ECs via activation of the ERK1/2 and AKT pathways. 
 
Future perspective 
As discussed above, the over-production and secretion of CathD could substantially contribute 
to tumor progression via directly influencing cancer cells and stromal cells such as fibroblasts 
and ECs non-proteolytically, and indirectly by cleaving ECM proteins, cytokines and 
chemokines locally. We recently showed that exogenous CathD promotes proliferation and 
migration in human omental microvascular ECs in ovarian cancer metastasis via inducing 
phosphorylation of the ERK1/2 and PI3K/AKT pathways in a proteolytic-independent manner 
[11], suggesting activation of a receptor tyrosine kinase. Recently, CathD was shown to induce 
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outgrowth of fibroblasts by binding to the LRP1 receptor which could potentially play a role 
in CAF proliferation in the tumor microenvironment, further aiding tumor growth [110]. A 
number of conventional anti-cancer strategies such as chemotherapy, radiotherapy and 
antiangiogenic therapy, are available to treat advanced disease. Importantly, antiangiogenic 
therapies such as anti-VEGF monoclonal antibody bevacizumab (Avastin) [115, 116], have 
been used clinically, but many have reported side-effects that limit safety in patients [117-120]. 
Recently, extracellular proteolytically active CathD was shown to play a pathogenic role in 
non-alcoholic steatohepatitis, particularly in regulating hepatic inflammation and 
dyslipidaemia [121], and it was demonstrated that inhibiting this enzyme protected mice from 
fatty liver disease [122]. Therefore, novel therapeutic targets, such as extracellular CathD, both 
in its proteolytic and non-proteolytic form, are urgently required. 
Ashraf et al. recently demonstrated an anti-tumor efficacy for anti-CathD antibody in triple-
negative breast cancer (TNBC) mice models [17]. TNBC, which accounts for 15-20% of all 
breast cancer cases, lacks overexpression of estrogen receptors, progesterone receptors and 
human epidermal growth factor receptor 2 (HER-2) [123]. Thus, the only available treatments 
are surgery, chemotherapy, and radiotherapy. Targeting extracellular CathD, which is 
overexpressed in TNBC [124], and is a strong marker for poor prognosis in breast cancer 
patients (with potent pro-tumorigenic effects) [11, 12, 24, 96, 125], via an immunotherapy 
approach could be of clinical significance. The authors in this recent study reported that two 
human anti-CathD antibodies efficiently bound to human and mouse CathD, even at the low 
pH of the TNBC microenvironment and significantly inhibited tumor growth in three different 
TNBC mouse models (MDA-MB-231 cell xenografts and two TNBC patient-derived 
xenografts) without apparent toxic effects [17]. Interestingly, the antibody prevented the 
recruitment of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells 
within the tumor, which are known to play a role in tumor immunosuppression. In peritoneal 
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metastases, such as high-grade serous carcinoma (advanced ovarian cancer), TAMs constitute 
over 50% of cells in the peritoneal tumor implants and ascites [126]. CathD overexpression 
and hypersecretion are also observed in tumor-associated omental mesothelium and in ascites 
from patients [23] and ovarian tumor conditioned media [55], and CathD is now known to 
induce a proangiogenic effect in the tumor microenvironment [11]. Therefore, targeting CathD 
utilizing an immunotherapy approach may be safer and more efficacious in treating ovarian 
carcinoma. However, bioavailability, selective targeting, and drug-delivery pose greater 
challenges which would require further research. 
Due to the complexity the tumor microenvironment presents, conventional drug delivery 
systems fail to deliver the chemotherapeutics at an effective concentration to selectively kill 
cancer cells and therefore can be associated with debilitating side effects. Thus, studies have 
been conducted to investigate alternative approaches to drug delivery such as utilizing 
nanotechnology. In recent years, nanomedicine and its underpinning sciences have 
significantly contributed to drug bioavailability and therapeutic index in cancer therapy. FDA 
approved nanostructures/chemo drugs such as liposomal formulation of doxorubicin (DOX) 
(Doxil® or Caelex®), daunorubicin (DaunoXome®) and albumin-bound paclitaxel (PTX) 
(Abraxane®) have been in use, however clinically, these formulations proved to be moderately 
successful due to inadequate delivery to the tumor microenvironment [127]. Therefore, in an 
attempt to target CathD, we developed a graphene-based compound (graphene oxide), that 
breaks down and adsorbs this protein [16]. Important characteristics of graphene oxide such as 
surface charge, large surface area, electronic features, chemical reactivity, and good 
bioavailability were utilized to entrap CathD in vitro [16]. Our data demonstrated that 
adsorption of CathD led to denaturation of the enzyme on the surface of graphene oxide. This 
promising outcome was also observed at low concentrations of graphene oxide, which 
remained non-toxic to cells in vitro. Thus, future work could address further development to 
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integrate targeted and safe delivery of graphene oxide to the tumor sites and testing of this 
compound in the tumor microenvironment in vivo tumor models, with a proven clearance of 
disseminated CathD and extracellular enzyme-targeting specificities. 
Conclusions 
The complexity of the tumor microenvironment such as the crosstalk between the cellular and 
non-cellular components, along with the barrier to drug delivery, poses greater challenges in 
discovering newer targets in cancer therapy. Conventional anti-cancer strategies have been the 
strongest weapons in defeating tumor, although, most of these fail to shrink tumors at 
secondary sites, limiting effective treatment. Current antiangiogenic therapies, in combination 
with chemotherapies moderately increase progression free survival, with side effects that could 
be life threatening. Therefore, newer targets within the microenvironment, such as extracellular 
CathD, which has a dual functionality, may hold greater promise in reducing breast and ovarian 
cancer progression.  
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